Regional resistance surveillance program results for 12 Asia-Pacific nations (2011)

Simple item page
dc.contributor.authorMendes, R.
dc.contributor.authorMendoza, M.
dc.contributor.authorBanga Singh, K.
dc.contributor.authorCastanheira, M.
dc.contributor.authorBell, J.
dc.contributor.authorTurnidge, J.
dc.contributor.authorLin, S.
dc.contributor.authorJones, R.
dc.date.issued2013
dc.description.abstractThe Regional Resistance Surveillance program monitored susceptibility rates and developing resistance by geographic region, including 12 Asia-Pacific (APAC) countries. Reference broth microdilution methods for susceptibility/interpretations were applied, processing 5,053 strains. Among Staphylococcus aureus isolates (37% methicillin-resistant S. aureus [MRSA], highest in South Korea [73%]), linezolid (LZD), tigecycline (TIG), and vancomycin were 100% active, but 33 and 34% of strains were levofloxacin (LEV) or macrolide resistant, respectively. Streptococcus pneumoniae was most resistant to β-lactams and macrolides (45%) but was LZD, LEV, and TIG susceptible (>98%). Extended-spectrum β-lactamase (ESBL) phenotype rates in Escherichia coli and Klebsiella spp. were 48 and 47%, respectively, and were highest in Taiwan, at 75 to 91%. The best anti-ESBL-phenotype agents were amikacin (81 to 96% susceptible), colistin (COL; >98%), TIG (>98%), and carbapenems (81 to 97%). Pseudomonas aeruginosa showed ≥20% resistance to all drugs except COL (99% susceptible). In conclusion, endemic evolving antimicrobial resistances in APAC nations show compromised roles for many commonly used antimicrobials.
dc.description.statementofresponsibilityRodrigo E. Mendes, Myrna Mendoza, Kirnpal K. Banga Singh, Mariana Castanheira, Jan M. Bell, John D. Turnidge, Stephen S. F. Lin, Ronald N. Jones
dc.identifier.citationAntimicrobial Agents and Chemotherapy, 2013; 57(11):5721-5726
dc.identifier.doi10.1128/AAC.01121-13
dc.identifier.issn0066-4804
dc.identifier.issn1098-6596
dc.identifier.orcidTurnidge, J. [0000-0003-4240-5578]
dc.identifier.urihttp://hdl.handle.net/2440/81509
dc.language.isoen
dc.publisherAmer Soc Microbiology
dc.rightsCopyright © 2013, American Society for Microbiology. All Rights Reserved.
dc.source.urihttps://doi.org/10.1128/aac.01121-13
dc.subjectHumans
dc.subjectPseudomonas aeruginosa
dc.subjectEscherichia coli
dc.subjectKlebsiella
dc.subjectStaphylococcus aureus
dc.subjectStreptococcus pneumoniae
dc.subjectGram-Negative Bacterial Infections
dc.subjectGram-Positive Bacterial Infections
dc.subjectAnti-Bacterial Agents
dc.subjectMicrobial Sensitivity Tests
dc.subjectDrug Resistance, Multiple, Bacterial
dc.subjectAsia
dc.subjectAustralia
dc.subjectNew Zealand
dc.subjectEpidemiological Monitoring
dc.titleRegional resistance surveillance program results for 12 Asia-Pacific nations (2011)
dc.typeJournal article
pubs.publication-statusPublished

Files

Collections

Molecular and Biomedical Science publications